Treace Medical Concepts, Inc. (NASDAQ:TMCI) Shares Sold by Charles Schwab Investment Management Inc.

Charles Schwab Investment Management Inc. decreased its stake in shares of Treace Medical Concepts, Inc. (NASDAQ:TMCI) by 10.6% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 349,510 shares of the company’s stock after selling 41,523 shares during the period. Charles Schwab Investment Management Inc. owned approximately 0.56% of Treace Medical Concepts worth $2,600,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently made changes to their positions in TMCI. Bank of New York Mellon Corp boosted its holdings in shares of Treace Medical Concepts by 2.6% in the fourth quarter. Bank of New York Mellon Corp now owns 125,945 shares of the company’s stock valued at $937,000 after acquiring an additional 3,215 shares in the last quarter. Palumbo Wealth Management LLC boosted its stake in Treace Medical Concepts by 71.3% during the 4th quarter. Palumbo Wealth Management LLC now owns 22,259 shares of the company’s stock valued at $166,000 after purchasing an additional 9,263 shares in the last quarter. Rhumbline Advisers increased its position in shares of Treace Medical Concepts by 2.0% during the 4th quarter. Rhumbline Advisers now owns 66,073 shares of the company’s stock valued at $492,000 after purchasing an additional 1,300 shares during the period. SG Americas Securities LLC raised its stake in shares of Treace Medical Concepts by 20.4% in the 4th quarter. SG Americas Securities LLC now owns 28,404 shares of the company’s stock worth $211,000 after buying an additional 4,813 shares in the last quarter. Finally, Ballentine Partners LLC raised its stake in shares of Treace Medical Concepts by 10.2% in the 4th quarter. Ballentine Partners LLC now owns 25,009 shares of the company’s stock worth $186,000 after buying an additional 2,314 shares in the last quarter. 84.08% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

A number of research analysts recently issued reports on TMCI shares. BTIG Research raised Treace Medical Concepts from a “neutral” rating to a “buy” rating and set a $16.00 target price on the stock in a report on Tuesday, February 4th. Lake Street Capital started coverage on shares of Treace Medical Concepts in a research note on Tuesday, December 31st. They issued a “buy” rating and a $14.50 price objective on the stock. JPMorgan Chase & Co. reiterated a “neutral” rating and issued a $8.00 target price on shares of Treace Medical Concepts in a report on Tuesday, December 17th. Finally, Truist Financial reduced their target price on shares of Treace Medical Concepts from $10.00 to $9.50 and set a “hold” rating for the company in a report on Thursday, March 13th. Five investment analysts have rated the stock with a hold rating and two have given a buy rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Hold” and an average price target of $10.14.

Insider Transactions at Treace Medical Concepts

In related news, insider Sean F. Scanlan sold 50,000 shares of the firm’s stock in a transaction that occurred on Monday, March 17th. The shares were sold at an average price of $7.97, for a total value of $398,500.00. Following the completion of the transaction, the insider now owns 364,081 shares of the company’s stock, valued at approximately $2,901,725.57. This trade represents a 12.07 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. 24.43% of the stock is currently owned by insiders.

Treace Medical Concepts Price Performance

NASDAQ TMCI opened at $8.37 on Friday. Treace Medical Concepts, Inc. has a 1 year low of $3.92 and a 1 year high of $13.24. The stock’s 50-day moving average price is $9.24 and its two-hundred day moving average price is $7.54. The company has a market cap of $524.12 million, a PE ratio of -8.45 and a beta of 0.77. The company has a current ratio of 4.12, a quick ratio of 2.98 and a debt-to-equity ratio of 0.51.

Treace Medical Concepts Company Profile

Treace Medical Concepts, Inc, a medical technology company, designs, manufactures, and markets medical devices in the United States. The company offers Lapiplasty 3D bunion correction system that combines instruments, implants, and surgical methods designed to surgically correct three planes of the bunion deformity.